Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis

Clinical Therapeutics

Volumn 21, Issue 1, 1999, Pages 172-188

  DeAbate, C Andrew ^a   Bettis, Robert ^b   Munk, Zev M ^c   Fleming, Harold ^d   Munn, Nancy J ^e   Riffer, Ernie ^f   Bagby, Barbara ^g   Giguere, Gregory ^g   Collins, Jeffrey J ^g  

^a Medical Research Centers   (United States)

^b Edmonds Family Medical Center   (United States)

^c Breco Research   (United States)

^d MeDQuest Inc   (United States)

^e MARSHALL UNIVERSITY   (United States)

^f Central Phoenix Medical Clinic   (United States)

^g GLAXOSMITHKLINE   (United States)

Author keywords

Chronic bronchitis; Fluoroquinolone; Grepafloxacin; Short course therapy

Indexed keywords

BETA LACTAMASE; GREPAFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MORAXELLA CATARRHALIS; PATIENT COMPLIANCE; PENICILLIN RESISTANCE; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0032971498     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88277-6     Document Type: Article

References (30)

1. 1. Ball P, Make B. Acute exacerbations of chronic bronchitis: An international comparison. Chest. 1998;113(Suppl):S199-S204.
2. 2. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.
3. 3. Gump DW, Phillips CA, Forsyth BR, et al. Role of infection in chronic bronchitis. Am Rev Respir Dis. 1976;113:465-474.
4. 4. Kayser FH. Changes in the spectrum of organisms causing respiratory tract infections: A review. Postgrad Med J. 1992;68(Suppl 3):S17-S23.
5. 5. Grossman RF. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest. 1997;112(Suppl):S310-S313.
6. 6. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995;8:1398-1420.
7. 7. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: A meta-analysis. JAMA. 1995;273:957-960.
8. 8. Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med. 1995;99(Suppl):3S-7S.
9. 9. Doern GV, Brueggemann A, Holley HP Jr., et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from out-patients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996;40:1208-1213.
10. 10. Doern GV, Brueggemann AB, Pierce G, et al. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996;40:2884-2886.
11. 11. Doern GV, Brueggemann AB, Pierce G, et al. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: Results of a national multicenter surveillance study. Antimicrob Agents Chemother. 1997;41:292-297.
12. 12. Imada T, Miyazaki S, Nishida M, et al. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Antimicrob Agents Chemother. 1992;36:573-579.
13. 13. Marco F, Jones RN, Hoban DJ, et al. Invitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: A multicentre international study. J Antimicrob Chemother. 1994;33:647-654.
14. 14. Cook PJ, Andrews JM, Wise R, et al. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J Antimicrob Chemother. 1995;35:317-326.
15. 15. Efthymiopoulos C, Bramer SL, Maroli A. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. Clin Pharmacokinet. 1997;33(Suppl 1):1-8.
16. 16. Cramer JA. Enhancing patient compliance in the elderly. Role of packaging aids and monitoring. Drugs Aging. 1998;12:7-15.
17. 17. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150:1881-1884.
18. 18. New antimicrobial agents approved by the US Food and Drug Administration in 1997 and new indications for previously approved agents. Antimicrob Agents Chemother. 1998;42:987-988.
19. 19. Ikeda A, Nishimura K, Izumi T, et al. Pharmacological treatment in acute exacerbations of chronic obstructive pulmonary disease. Drugs Aging. 1998;12:129-137.
20. 20. Lorenz J, Steinfeld P, Drath L, et al. Efficacy and tolerability of 5- vs 10-day cefixime therapy in acute exacerbations of chronic bronchitis. Clin Drug Invest. 1998;15:13-20.
21. 21. Performance Standards for Antimicrobial Disk Susceptibility Tests - 6th Edition: Approved Standard. Wayne, Pa: National Committee for Clinical Laboratory Standards; 1997:1-26.
22. 22. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - 4th Edition: Approved Standard. Wayne, Pa: National Committee for Clinical Laboratory Standards; 1997:1-29.
23. 23. Langan CE, Cranfield R, Breisch S, et al. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother. 1997;40(Suppl A):63-72.
24. 24. Chodosh S, Lakshminarayan S, Swarz H, et al. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: Comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. Antimicrob Agents Chemother. 1998;42:114-120.
25. 25. DeAbate C, Myers D, Henry D, et al. Comparative safety and efficacy of once-daily grepafloxacin in the treatment of ABECB. Clin Drug Invest. In press.
26. 26. Watanabe A, Kikuchi H, Takahashi H, et al. In vitro antimicrobial activity, penetration into sputum and therapeutic efficacy of grepafloxacin in respiratory tract infections. Jpn J Chemother. 1995;43:206-216.
27. 27. Fuchs PC, Barry AL, Brown SD. Tentative interpretive criteria for testing the susceptibility of Streptococcus pneumoniae to eight fluoroquinolones. Diagn Microbiol Infect Dis. 1996;26:23-27.
28. 28. Wise R, Andrews JM. The activity of grepafloxacin against respiratory pathogens in the UK. J Antimicrob Chemother. 1997;40(Suppl A):27-30.
29. 29. Sclar DA, Tartaglione TA, Fine MJ. Overview of issues related to medical compliance with implications for the out-patient management of infectious diseases. Infect Agents Dis. 1994;3:266-273.
30. 30. Reyes H, Guiscafre H, Munoz O, et al. Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea. J Clin Epidemiol. 1997;50:1297-1304.